Genmab reports Phase 1/2 trial results for Rina‑S in platinum‑resistant ovarian cancer
Genmab A/S presented data from Part C of its Phase 1/2 RAINFOL‑01 trial of the antibody‑drug conjugate rinatabart sesutecan (Rina‑S) in patients with platinum‑resistant ovarian cancer. The study enrolled 109 heavily pre‑treated patients and showed a confirmed objective response rate of 45.9% with a median duration of response of 12.1 months and median progression‑free survival of 9.5 months. Common adverse events were fatigue, nausea and anemia, and treatment discontinuation due to toxicity occurred in 5.5% of participants. The results were presented at the International Gynecologic Cancer Society Congress 2026 in Montreal.
Why it matters
Genmab says the durable responses and manageable safety profile support continued advancement of Rina‑S in its four ongoing Phase 3 trials, which could eventually generate revenue if the drug gains approval. Investors may view the data as a positive catalyst for the company’s pipeline and valuation.
Key facts
- 1The Part C cohort enrolled 109 patients with platinum‑resistant ovarian cancer. investing.com
- 2Confirmed objective response rate was 45.9% (95% CI 36.3‑55.7) including five complete responses. investing.com
- 3Median duration of response was 12.1 months (95% CI 6.5‑15.4). finanznachrichten.de
- 4Median progression‑free survival was 9.5 months (95% CI 7.6‑11.3). investing.com
- 557.8% of patients experienced fatigue; 67.9% experienced nausea; 57.8% experienced anemia. investing.com
- 6Treatment discontinuation due to adverse events occurred in 5.5% of participants. finanznachrichten.de
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.